Ascendis Pharma, a clinical-stage company, is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. TransCon Growth Hormone, ASND’s lead program, has advanced to a pivotal heiGHt Trial for once-weekly dosing in pediatric patients.